利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.026 秒)

    Humanized immunoglobulin reactive with alpha4beta7 integrin
    2.
    发明申请
    Humanized immunoglobulin reactive with alpha4beta7 integrin 有权
    人源化免疫球蛋白与α4β7整合素反应

    公开(公告)号：US20060292140A1

    公开(公告)日：2006-12-28

    申请号：US11511164

    申请日：2006-08-28

    申请人： Paul Ponath ,  Douglas Ringler ,  S. Jones ,  Walter Newman ,  Jose Saldanha ,  Mary Bendig

    发明人： Paul Ponath ,  Douglas Ringler ,  S. Jones ,  Walter Newman ,  Jose Saldanha ,  Mary Bendig

    IPC分类号： A61K39/395 ,  C07K16/44 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06

    CPC分类号： C07K16/2839 ,  A61K38/00 ,  C07K14/70503 ,  C07K2317/24 ,  C07K2319/00

    摘要： The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human α4β7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody.

    摘要翻译： 本发明涉及对α4β7整联蛋白具有结合特异性的人源化免疫球蛋白，其包含非人来源的抗原结合区（例如，啮齿动物）和至少一部分人来源的免疫球蛋白（例如人框架区，人恒定区 ）。 在一个实施方案中，人源化免疫球蛋白可与鼠Act-1竞争结合人α4β7整联蛋白。 在优选的实施方案中，人源化免疫球蛋白的抗原结合区包含鼠Act-1抗体的轻链和重链的互补决定区的每一个。

    Human chemotactic cytokine
    7.
    发明申请
    Human chemotactic cytokine 失效

    公开(公告)号：US20060141567A1

    公开(公告)日：2006-06-29

    申请号：US11133140

    申请日：2005-05-19

    申请人： Paul Ponath ,  Shixin Qin ,  Douglas Ringler ,  Walter Newman ,  Charles Mackay

    发明人： Paul Ponath ,  Shixin Qin ,  Douglas Ringler ,  Walter Newman ,  Charles Mackay

    IPC分类号： C12P21/06 ,  C07H21/04 ,  C07K14/74

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K47/642 ,  C07K14/523 ,  C07K14/7158 ,  C07K2317/76 ,  C07K2319/00

    摘要： The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.